Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.81
$2.24
52-Week Range
N/A
Volume
2,579 shs
Average Volume
162,968 shs
Market Capitalization
$8.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

REXN Stock News Headlines

Aurinia Pharmaceuticals Inc AUPH
The Pentagon just made a National Security move...
This "awesome resource" could power America for 30,000 years... We sent one of our smartest researchers.... a consultant who's worked for the likes of J.P. Morgan and Citicorp... into the middle of the Utah desert with a film crew.Why? So he could lead an investigation into a radical new kind of energy that's so abundant, the Dept. of Energy says it could meet America's power needs for the next 2 million years. It's got nothing to do with wind, solar, nuclear, oil or gas.
Rexahn: Holes Galore in Serdaxin Data
See More Headlines

REXN Stock Analysis - Frequently Asked Questions

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) released its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.34.

Rexahn Pharmaceuticals shares reverse split on Friday, April 12th 2019.The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
8/07/2019
Today
7/02/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REXN
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.64 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$8.11 million
Optionable
Optionable
Beta
0.98
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:REXN) was last updated on 7/2/2025 by MarketBeat.com Staff
From Our Partners